BIOVF Statistics

Total Valuation

Swedish Orphan Biovitrum AB has a market cap or net worth of 9.76 billion. The enterprise value is 11.30 billion.

Market Cap	9.76B
Enterprise Value	11.30B

Important Dates

The next estimated earnings date is Wednesday, February 5, 2025.

Earnings Date	Feb 5, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+11.98%
Shares Change (QoQ)	+0.61%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	219.73M

Valuation Ratios

The trailing PE ratio is 28.18.

PE Ratio	28.18
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.28, with an EV/FCF ratio of 18.03.

EV / Earnings	32.60
EV / Sales	5.01
EV / EBITDA	13.28
EV / EBIT	21.03
EV / FCF	18.03

Financial Position

The company has a current ratio of 0.91, with a Debt / Equity ratio of 0.48.

Current Ratio	0.91
Quick Ratio	0.62
Debt / Equity	0.48
Debt / EBITDA	1.86
Debt / FCF	2.81
Interest Coverage	4.44

Financial Efficiency

Return on equity (ROE) is 9.82% and return on invested capital (ROIC) is 6.86%.

Return on Equity (ROE)	9.82%
Return on Assets (ROA)	5.13%
Return on Capital (ROIC)	6.86%
Revenue Per Employee	1.38M
Profits Per Employee	190,997
Employee Count	1,772
Asset Turnover	0.34
Inventory Turnover	1.37

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +7.81% in the last 52 weeks. The beta is 0.23, so Swedish Orphan Biovitrum AB's price volatility has been lower than the market average.

Beta (5Y)	0.23
52-Week Price Change	+7.81%
50-Day Moving Average	26.04
200-Day Moving Average	23.16
Relative Strength Index (RSI)	51.01
Average Volume (20 Days)	684

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Swedish Orphan Biovitrum AB had revenue of 2.51 billion and earned 346.47 million in profits. Earnings per share was 0.99.

Revenue	2.51B
Gross Profit	1.97B
Operating Income	597.50M
Pretax Income	414.80M
Net Income	346.47M
EBITDA	932.13M
EBIT	597.50M
Earnings Per Share (EPS)	0.99

Full Income Statement

Balance Sheet

The company has 58.57 million in cash and 1.76 billion in debt, giving a net cash position of -1.70 billion.

Cash & Cash Equivalents	58.57M
Total Debt	1.76B
Net Cash	-1.70B
Net Cash Per Share	n/a
Equity (Book Value)	3.66B
Book Value Per Share	10.65
Working Capital	-123.64M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 656.95 million and capital expenditures -30.47 million, giving a free cash flow of 626.48 million.

Operating Cash Flow	656.95M
Capital Expenditures	-30.47M
Free Cash Flow	626.48M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 78.60%, with operating and profit margins of 23.83% and 13.82%.

Gross Margin	78.60%
Operating Margin	23.83%
Pretax Margin	16.54%
Profit Margin	13.82%
EBITDA Margin	37.17%
EBIT Margin	23.83%
FCF Margin	24.98%

Dividends & Yields

Swedish Orphan Biovitrum AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.98%
Shareholder Yield	-11.98%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Swedish Orphan Biovitrum AB has an Altman Z-Score of 2.58. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.58
Piotroski F-Score	n/a